[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 867
1. Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW: Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders. Clin Lymphoma Myeloma; 2007 Jul;7(7):462-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders.
  • In patients with MM, plasma levels of several prothrombotic coagulation factors are increased, and this can contribute to the prothrombotic state of these patients.
  • Recently, an increased thrombosis risk has also been described for other plasma cell disorders (PCDs), such as monoclonal gammopathy of uncertain significance (MGUS) and systemic amyloidosis.
  • The aim of this study was to analyze prothrombotic coagulation disorders in patients with paraprotein-producing B-cell disorders, such as MGUS, systemic amyloidosis, Waldenström's macroglobulinemia, and MM.
  • PATIENTS AND METHODS: An increase in factor VIII and von Willebrand factor was observed in patients with MGUS and systemic amyloidosis that was similar to increases seen in patients with untreated MM.

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875234.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Coagulation Factors; 0 / Paraproteins
  •  go-up   go-down


2. Garces-Sanchez M, Dyck PJ, Kyle RA, Zeldenrust S, Wu Y, Ladha SS, Klein CJ: Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle Nerve; 2008 Apr;37(4):490-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-MAG and the cross-reacted sulfoglucuronyl paragloboside antibodies (SGPG) were studied in 46 patients with IgM amyloidosis (21 with polyneuropathy), and 21 matched IgM MGUS (monoclonal gammopathies of undetermined significance) controls without neuropathy.
  • Low levels of anti-MAG antibodies were found in 12 of 21 IgM MGUS controls without neuropathy (mean follow-up, 11 years).
  • We conclude that finding serum anti-MAG antibodies does not exclude the diagnosis of primary amyloidosis.

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236455.001).
  • [ISSN] 0148-639X
  • [Journal-full-title] Muscle & nerve
  • [ISO-abbreviation] Muscle Nerve
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 62242; United States / NINDS NIH HHS / NS / NS 36797
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Globosides; 0 / Immunoglobulin M; 0 / Myelin-Associated Glycoprotein; 0 / sulfate-3-glucuronyl paragloboside
  •  go-up   go-down


3. Au GG, Lincz LF, Enno A, Shafren DR: Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol; 2007 Apr;137(2):133-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.
  • This study assessed the capacity of Coxsackievirus A21 (CVA21) to target and destroy multiple myeloma (MM) and precursor aberrant plasma cells in vitro using established MM cell lines and 15 patient bone marrow (BM) biopsies [n = 10 MM and five monoclonal gammopathy of undetermined significance (MGUS)].
  • Cell surface analysis revealed that all tumour cells lines expressed high levels of intercellular adhesion molecule-1 (ICAM-1) and decay-accelerating factor (DAF), the receptor molecules to which CVA21 can bind, leading to subsequent cell-entry and infection.
  • MM cell lines were remarkably susceptible to CVA21 lytic infection, producing 100-1000-fold increases in viral progeny within 24 h.
  • Furthermore, challenge of patient BM biopsies with CVA21 for 48 h resulted in specific purging of up to 98.7% of CD138+ plasma cells, with no significant decrease in progenitor cell function.
  • Data generated in this study suggests that CVA21 virotherapy may have potential applications as a systemic anti-tumour agent for MM, or in the ex vivo purging of malignant plasma cells prior to autologous stem cell transplantation.
  • [MeSH-minor] Antigens, CD55 / metabolism. Bone Marrow Cells / pathology. Bone Marrow Purging / methods. Cell Death. Coculture Techniques. Colony-Forming Units Assay. Humans. Intercellular Adhesion Molecule-1 / metabolism. Leukocytes, Mononuclear / pathology. Leukocytes, Mononuclear / virology. Neoplasm Proteins / metabolism. Tumor Cells, Cultured. Virus Replication

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17391493.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD55; 0 / Neoplasm Proteins; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


Advertisement
4. Okura T, Miyoshi K, Nagao T, Jotoku M, Enomoto D, Irita J, Kurata M, Higaki J: Light chain deposition disease developing 15 years following the diagnosis of monoclonal gammopathy of undetermined significance. Intern Med; 2009;48(2):101-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Light chain deposition disease developing 15 years following the diagnosis of monoclonal gammopathy of undetermined significance.
  • Fifteen years previously she had been diagnosed with monoclonal gammopathy of undetermined significance (MGUS).
  • Her renal biopsy specimen revealed thickened basement membrane, mesangial cell proliferation and an increase in the mesangial matrix.
  • These findings confirmed a diagnosis of light chain deposit disease (LCDD) with MGUS.
  • The development of LCDD in patients with MGUS for fifteen years is very rare.

  • Genetic Alliance. consumer health - Light chain deposition disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145054.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


5. Aline-Fardin A, Rifle G, Martin L, Justrabo E, Bour JB, D'Athis P, Tanter Y, Mousson C: Recurent and de novo membranous glomerulopathy after kidney transplantation. Transplant Proc; 2009 Mar;41(2):669-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurent and de novo membranous glomerulopathy after kidney transplantation.
  • The aim of this study was to compare the clinical characteristics of recurrent and de novo membranous glomerulopathy (MG) among a cohort of 614 recipients transplanted between 1989 and 2006.
  • The diagnosis was established on protocol biopsies performed 1, 2, 4, or 8 years after transplantation or because of proteinuria/nephrotic syndrome and/or an increased serum creatinine level.
  • HCV infection, cryoglobulinemia, monoclonal gammopathy, skin cancers, Kaposi sarcoma, diabetes mellitus, anti-HLA antibodies, and graft survival were not significantly different between the groups.
  • Seventeen MG were diagnosed in 15 patients (2.45% of the whole group), including 6 recurrent MG (35%) and 11 de novo MG (75%).
  • Recurrent MG occurred earlier than de novo MG (15.58 +/- 19.13 vs 49.27 +/- 32.71 months).
  • Recipients with de novo MG were more frequently infected with HCV, which seemed to be the main etiologic factor for de novo MG, and may be linked to a Th2 polarization of the immune response.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328952.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


6. Dupont SA, Dispenzieri A, Mauermann ML, Rabinstein AA, Brown RD Jr: Cerebral infarction in POEMS syndrome: incidence, risk factors, and imaging characteristics. Neurology; 2009 Oct 20;73(16):1308-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To determine the risk factors and incidence of cerebral infarction associated with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome.
  • METHODS: The Mayo Clinic dysproteinemia database was queried to identify patients with coded diagnosis of POEMS syndrome.
  • Evidence of plasma cell proliferation within the bone marrow and elevated serum platelet count led to increased risk of cerebral infarction in this population.
  • [MeSH-minor] Adult. Aged. Bone Marrow / pathology. Bone Marrow / physiopathology. Brain / pathology. Brain / radiography. Cell Proliferation. Cohort Studies. Databases, Factual. Female. Humans. Incidence. Magnetic Resonance Imaging. Male. Middle Aged. Plasma Cells / pathology. Plasma Cells / physiology. Platelet Count. Retrospective Studies. Risk Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - POEMS syndrome.
  • MedlinePlus Health Information. consumer health - Stroke.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Apr 1;101(7):2496-506 [12456500.001]
  • [Cites] J Stroke Cerebrovasc Dis. 2007 Nov-Dec;16(6):278-84 [18035247.001]
  • [Cites] Eur J Neurol. 2003 Jul;10(4):383-4 [12823489.001]
  • [Cites] Nervenarzt. 2004 Aug;75(8):790-4 [15007508.001]
  • [Cites] Stroke. 1993 Jan;24(1):35-41 [7678184.001]
  • [Cites] Semin Arthritis Rheum. 1992 Dec;22(3):151-61 [1295088.001]
  • [Cites] Stroke. 1994 Jan;25(1):40-3 [8266381.001]
  • [Cites] Medicine (Baltimore). 1996 Jul;75(4):226-32 [8699962.001]
  • [Cites] J Intern Med. 1996 Aug;240(2):107-9 [8810938.001]
  • [Cites] J Rheumatol. 1998 Apr;25(4):813-5 [9558193.001]
  • [Cites] Schweiz Med Wochenschr. 1998 Jun 27;128(26):1059-64 [9700780.001]
  • [Cites] Angiology. 1998 Nov;49(11):937-40 [9822051.001]
  • [Cites] Eur J Neurol. 2006 Jan;13(1):99-102 [16420405.001]
  • [Cites] Ann Hematol. 2007 Jan;86(1):59-61 [16953376.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 May 18;56(19):469-74 [17510610.001]
  • [Cites] Curr Drug Targets. 2007 Jul;8(7):794-801 [17630932.001]
  • [Cites] Clin Rheumatol. 2007 Nov;26(11):1989-92 [17410319.001]
  • [Cites] Arch Neurol. 2003 May;60(5):745-9 [12756139.001]
  • (PMID = 19841383.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2764416
  •  go-up   go-down


7. Terrier B, Lacroix C, Guillevin L, Hatron PY, Dhote R, Maillot F, Diot E, Sarrot-Reynauld F, Sordet C, Dubourg O, Meyer L, Mariette X, Gottenberg JE, Club Rhumatismes et Inflammation: Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy. Arthritis Rheum; 2007 Dec 15;57(8):1520-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Patients with vasculitis (lymphocytic [n = 8] or necrotizing [n = 14]) had a higher prevalence of acute-onset neuropathy, multiple mononeuropathy, sensorimotor involvement, vascular purpura, general symptoms, increased C-reactive protein level, positivity for rheumatoid factor, hypocomplementemia, and monoclonal gammopathy compared with those without vasculitis (n = 18).
  • Regarding clinical evolution, the results of NMB (P < 0.0001), in particular the presence of necrotizing vasculitis (P < 0.001), an acute neuropathy onset (P < 0.0001), general symptoms (P < 0.0001), multiple mononeuropathy (P = 0.0007), presence of sensorimotor involvement (P = 0.002), and increased C-reactive protein level (P = 0.008), were significantly associated with a better outcome in univariate analysis.
  • [MeSH-major] Muscle, Skeletal / pathology. Peripheral Nervous System Diseases / diagnosis. Peripheral Nervous System Diseases / etiology. Sjogren's Syndrome / complications. Sural Nerve / pathology
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Biopsy. C-Reactive Protein / metabolism. Disease Progression. Female. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Vasculitis / diagnosis. Vasculitis / etiology. Vasculitis / pathology

  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050172.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Immunosuppressive Agents; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


8. Randi ML, Ruzzon E, Tezza F, Tezza F, Pacquola E, Fabris F: Monoclonal gammopathy in human leishmaniasis. Neth J Med; 2006 Feb;64(2):50-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal gammopathy in human leishmaniasis.
  • A 64-year-old female with IgGk monoclonal components (total 45 g/l) and 30% abnormal plasma cells and plasmoblasts in bone marrow is reported.
  • After the identification of leishmania in the bone marrow, liposomal amphotericin B was used and a progressive resolution of the gammopathy was documented.
  • [MeSH-major] Amphotericin B / therapeutic use. Antiprotozoal Agents / therapeutic use. Bone Marrow Diseases / parasitology. Leishmaniasis, Visceral / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunoglobulin G / blood. Liposomes. Middle Aged. Paraproteinemias / blood

  • Genetic Alliance. consumer health - Leishmaniasis.
  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517989.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiprotozoal Agents; 0 / Immunoglobulin G; 0 / Liposomes; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


9. Lannert H, Able T, Becker S, Sommer M, Braun M, Stadtherr P, Ho AD: Optimizing BM harvesting from normal adult donors. Bone Marrow Transplant; 2008 Oct;42(7):443-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The experience at a single institution of BM harvesting (BMH) in general anesthetic for allogeneic transplantation from 49 healthy adult donors since March 2002 is presented in detail, together with an analysis of all the donor complications.
  • BMH accomplished by trained personal is a safe procedure for healthy adult donors on an outpatient basis as standard in our collection center.
  • [MeSH-major] Bone Marrow Cells / cytology. Bone Marrow Cells / physiology. Hematopoietic Stem Cell Transplantation / methods. Tissue and Organ Harvesting / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622419.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Hemoglobins; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


10. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA: Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem; 2005 May;51(5):878-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The quantitative assay for free light chains (FLCs) is a recently introduced commercial test reported to be sensitive and specific for detecting FLC diseases such as primary systemic amyloidosis (AL), light chain deposition disease (LCDD), nonsecretory multiple myeloma (NSMM), and light chain multiple myeloma.
  • The majority of these patients (88%) had bone marrow-derived monoclonal plasma cell disorders (PCDs).
  • The 121 patients who did not have monoclonal gammopathy all had FLC kappa/lambda ratios within the range of values obtained for a reference population in our laboratory.
  • Among the patients with monoclonal gammopathies were patients with multiple myeloma (330), AL (269), monoclonal gammopathy of undetermined significance (114), smoldering multiple myeloma (72), plasmacytoma (22), NSMM (20), macroglobulinemia (9), LCDD (7), and a variety of other PCDs.
  • Among the 110 AL patients who had not been previously treated and who had a FLC assay performed within 120 days of diagnosis, the FLC kappa/lambda ratio was positive in 91% compared with 69% for serum immunofixation electrophoresis (IFE) and 83% for urine IFE.
  • [MeSH-major] Amyloidosis / diagnosis. Immunoglobulin kappa-Chains / blood. Immunoglobulin lambda-Chains / blood. Paraproteinemias / diagnosis
  • [MeSH-minor] Clinical Laboratory Information Systems. Humans. Laboratories, Hospital. Medical Records Systems, Computerized. Multiple Myeloma / diagnosis. Plasmacytoma / diagnosis. Waldenstrom Macroglobulinemia / diagnosis

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Chem. 2005 May;51(5):805-7 [15855664.001]
  • (PMID = 15774572.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62242
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains
  •  go-up   go-down


11. Liebisch P, Eppinger S, Schöpflin C, Stehle G, Munzert G, Döhner H, Schmid M: CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica; 2005 Apr;90(4):489-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: Despite recent advances in the treatment of multiple myeloma (MM), this disease remains incurable in the majority of patients.
  • To investigate the applicability of this compound to clonal plasma cell disorders, we analyzed CD44v6 expression on malignant plasma cells from patients with multiple myeloma.
  • DESIGN AND METHODS: Bone marrow samples from 57 patients with monoclonal gammopathy of undetermined significance (MGUS), MM, and plasma cell leukemia (PCL) were examined for CD44v6 expression by using flow cytometry (FACS) analysis.
  • RESULTS: In only 1 of 16 cases (6%) with MGUS and 1 out of 6 cases (17%) with stage I MM were plasma cells CD44v6 positive.
  • These results suggest that this epitope is a potential new target for monoclonal antibodies such as bivatuzumab mertansine.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Humans. Leukemia, Plasma Cell / drug therapy. Leukemia, Plasma Cell / genetics. Leukemia, Plasma Cell / immunology. Male. Middle Aged. Paraproteinemias / drug therapy. Paraproteinemias / genetics. Paraproteinemias / immunology. Tumor Burden / immunology


12. Lalive PH, Passweg JR, Kuntzer T: [Neuropathy associated with monoclonal gammopathy (dysglobulinemia)]. Rev Med Suisse; 2009 Apr 29;5(201):962-4, 966-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuropathy associated with monoclonal gammopathy (dysglobulinemia)].
  • [Transliterated title] Neuropathies associées aux gammapathies monoclonales (dysglobulinémies).
  • Neurological complications of monoclonal gammopathy, or dysglobulinemia, are typically affecting the peripheral nerve.
  • The clinical course is often chronic and progressive and requires a precise diagnosis of the type of plasma cell disorder associated with the neuropathy, to investigate other organs manifestations and to assess the presence of specific markers.

  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476059.001).
  • [ISSN] 1660-9379
  • [Journal-full-title] Revue médicale suisse
  • [ISO-abbreviation] Rev Med Suisse
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


13. Müntener T, Rüfenacht S, Di Palma S, Hartmeier G, Welle M: Scleromyxedema-like syndrome with systemic involvement in a cat. Vet Pathol; 2010 Mar;47(2):346-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Scleromyxedema--the generalized form of lichen myxedematosus, a primary mucinosis--is a rare disease in human patients.
  • It is characterized by dermal mucin deposits, increased numbers of fibroblasts, and variable fibrosis in the absence of thyroid disease.
  • It is accompanied in 80% of cases by a monoclonal gammopathy.
  • This is the first report of a scleromyxedema-like syndrome in a cat, which had a substantial deposition of mucin in the dermis of the head and paws with a mild gammaglobulinemia of 2.25 g/dl (reference range, 1.39-2.22 g/dl).

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20110223.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Klintworth GK: Corneal dystrophies. Orphanet J Rare Dis; 2009 Feb 23;4:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The term corneal dystrophy embraces a heterogenous group of bilateral genetically determined non-inflammatory corneal diseases that are restricted to the cornea.
  • Knowledge about the responsible genetic mutations responsible for these disorders has led to a better understanding of their basic defect and to molecular tests for their precise diagnosis.
  • As clinical manifestations widely vary with the different entities, corneal dystrophies should be suspected when corneal transparency is lost or corneal opacities occur spontaneously, particularly in both corneas, and especially in the presence of a positive family history or in the offspring of consanguineous parents.
  • Main differential diagnoses include various causes of monoclonal gammopathy, lecithin-cholesterol-acyltransferase deficiency, Fabry disease, cystinosis, tyrosine transaminase deficiency, systemic lysosomal storage diseases (mucopolysaccharidoses, lipidoses, mucolipidoses), and several skin diseases (X-linked ichthyosis, keratosis follicularis spinolosa decalvans).
  • The management of the corneal dystrophies varies with the specific disease.
  • Other less debilitating or asymptomatic dystrophies do not warrant treatment.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cornea. 2002 Jul;21(5):524-9 [12072731.001]
  • [Cites] Br J Ophthalmol. 2002 Jul;86(7):729-32 [12084738.001]
  • [Cites] Cornea. 2002 Nov;21(8):787-91 [12410038.001]
  • [Cites] Front Biosci. 2003 May 1;8:d687-713 [12700042.001]
  • [Cites] Ophthalmology. 2004 Mar;111(3):463-8 [15019320.001]
  • [Cites] Ophthalmology. 2004 Jun;111(6):1108-14 [15177960.001]
  • [Cites] Klin Monbl Augenheilkd. 1976 Dec;169(6):717-27 [1087942.001]
  • [Cites] Arch Ophthalmol. 1977 Mar;95(3):440-4 [139144.001]
  • [Cites] Am J Ophthalmol. 1977 Apr;83(4):554-60 [141212.001]
  • [Cites] Am J Ophthalmol. 1977 May;83(5):629-32 [301356.001]
  • [Cites] Am J Ophthalmol. 1977 May;83(5):633-42 [301357.001]
  • [Cites] Arch Ophthalmol. 1977 Sep;95(9):1529-37 [302697.001]
  • [Cites] Br J Ophthalmol. 1978 Jan;62(1):39-45 [305258.001]
  • [Cites] Am J Ophthalmol. 1978 May;85(5 Pt 1):606-12 [306759.001]
  • [Cites] Arch Ophthalmol. 1978 Nov;96(11):2036-9 [309758.001]
  • [Cites] Arch Ophthalmol. 1970 Aug;84(2):179-92 [5311096.001]
  • [Cites] Arch Ophthalmol. 1979 Apr;97(4):664-70 [85445.001]
  • [Cites] Arch Ophthalmol. 1980 Jan;98(1):144-8 [6986141.001]
  • [Cites] Ophthalmology. 1983 Dec;90(12):1507-11 [6610848.001]
  • [Cites] Arthritis Rheum. 1985 Dec;28(12):1367-76 [2935158.001]
  • [Cites] Am J Ophthalmol. 1986 Nov 15;102(5):561-9 [2946233.001]
  • [Cites] Ophthalmic Paediatr Genet. 1986 Dec;7(3):139-43 [2951638.001]
  • [Cites] Eye (Lond). 1988;2 ( Pt 1):63-70 [3261696.001]
  • [Cites] Ophthalmologica. 1989;199(1):1-9 [2668837.001]
  • [Cites] Eye (Lond). 1989;3 ( Pt 4):446-54 [2606219.001]
  • [Cites] Acta Ophthalmol (Copenh). 1989 Dec;67(6):678-84 [2694746.001]
  • [Cites] Ophthalmology. 1990 Jan;97(1):104-9 [2314832.001]
  • [Cites] Acta Ophthalmol (Copenh). 1990 Jun;68(3):297-303 [2392905.001]
  • [Cites] Acta Ophthalmol (Copenh). 1990 Aug;68(4):384-9 [2220354.001]
  • [Cites] Cornea. 1992 Mar;11(2):93-101 [1582223.001]
  • [Cites] Am J Ophthalmol. 1992 Jul 15;114(1):35-44 [1621784.001]
  • [Cites] Ophthalmology. 1992 Oct;99(10):1564-8 [1454323.001]
  • [Cites] Am J Ophthalmol. 1993 May 15;115(5):644-52 [7683843.001]
  • [Cites] Arch Ophthalmol. 1993 Aug;111(8):1106-14 [8352693.001]
  • [Cites] Surv Ophthalmol. 1993 Sep-Oct;38(2):149-68 [8235998.001]
  • [Cites] Am J Ophthalmol. 1994 Apr 15;117(4):543-4 [8154546.001]
  • [Cites] Ophthalmology. 1994 May;101(5):895-901 [8190477.001]
  • [Cites] Ophthalmology. 1995 Apr;102(4):557-67 [7724173.001]
  • [Cites] Hum Mol Genet. 1995 Mar;4(3):485-8 [7795607.001]
  • [Cites] Hum Mol Genet. 1995 Dec;4(12):2395-8 [8634716.001]
  • [Cites] Ophthalmology. 1996 Mar;103(3):474-8 [8600425.001]
  • [Cites] Ophthalmology. 1996 Jul;103(7):1111-7 [8684802.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1996 Aug;16(8):992-9 [8696964.001]
  • [Cites] Curr Eye Res. 1996 Sep;15(9):965-72 [8921218.001]
  • [Cites] Nat Genet. 1997 Mar;15(3):247-51 [9054935.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):184-7 [9171831.001]
  • [Cites] Am J Ophthalmol. 1997 Jul;124(1):9-18 [9222226.001]
  • [Cites] Genomics. 1997 Nov 15;46(1):152-4 [9403072.001]
  • [Cites] Am J Med Genet. 1998 Jan 6;75(1):35-9 [9450854.001]
  • [Cites] Am J Hum Genet. 1998 Feb;62(2):320-4 [9463327.001]
  • [Cites] Am J Hum Genet. 1997 Dec;61(6):1268-75 [9399908.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):743-8 [9502416.001]
  • [Cites] Br J Ophthalmol. 1998 Apr;82(4):444-7 [9640198.001]
  • [Cites] Am J Hum Genet. 1998 Oct;63(4):1073-7 [9758629.001]
  • [Cites] Am J Ophthalmol. 1998 Oct;126(4):535-42 [9780098.001]
  • [Cites] Nippon Ganka Gakkai Zasshi. 1999 Oct;103(10):761-4 [10554552.001]
  • [Cites] Br J Ophthalmol. 2000 Jan;84(1):67-71 [10611102.001]
  • [Cites] Exp Eye Res. 2000 Jan;70(1):41-9 [10644419.001]
  • [Cites] Hum Mutat. 1998;12(3):215-6 [10660331.001]
  • [Cites] Br J Ophthalmol. 2000 May;84(5):527-30 [10781519.001]
  • [Cites] Cornea. 2000 Jul;19(4):570-3 [10928782.001]
  • [Cites] Ophthalmology. 2000 Sep;107(9):1761-4 [10964841.001]
  • [Cites] Nat Genet. 2000 Oct;26(2):237-41 [11017086.001]
  • [Cites] Am J Ophthalmol. 2000 Oct;130(4):461-8 [11024418.001]
  • [Cites] Curr Eye Res. 2000 Nov;21(5):891-6 [11262611.001]
  • [Cites] Ophthalmology. 2001 Apr;108(4):810-7 [11297503.001]
  • [Cites] Ophthalmology. 2001 Apr;108(4):818-23 [11297504.001]
  • [Cites] Mol Vis. 2000 Dec 13;6:261-4 [11139648.001]
  • [Cites] Hum Mol Genet. 2001 Oct 1;10(21):2415-23 [11689488.001]
  • [Cites] Hum Mol Genet. 2002 May 1;11(9):1029-36 [11978762.001]
  • [Cites] Mol Vis. 1998 Dec 31;4:31 [9873069.001]
  • [Cites] Jpn J Ophthalmol. 1998 Nov-Dec;42(6):450-5 [9886734.001]
  • [Cites] Br J Ophthalmol. 1999 Jan;83(1):115-9 [10209448.001]
  • [Cites] Cornea. 1999 Jul;18(4):424-9 [10422854.001]
  • [Cites] Genomics. 1999 Oct 1;61(1):1-4 [10512674.001]
  • [Cites] AMA Arch Ophthalmol. 1954 Apr;53(4):536-41 [14360886.001]
  • [Cites] Trans Ophthalmol Soc N Z. 1955;8:77-8 [13380984.001]
  • [Cites] Am J Pathol. 1964 Oct;45:565-86 [14217673.001]
  • [Cites] Trans Am Ophthalmol Soc. 1954-1955;52:133-44 [13274420.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Feb;46(2):420-6 [15671264.001]
  • [Cites] Am J Hum Genet. 2005 Jul;77(1):54-63 [15902656.001]
  • [Cites] Am J Hum Genet. 2005 Nov;77(5):694-708 [16252232.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4480-4 [16303937.001]
  • [Cites] Eur J Ophthalmol. 2005 Nov-Dec;15(6):804-8 [16329070.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Jan;47(1):140-5 [16384955.001]
  • [Cites] Am J Ophthalmol. 2006 Mar;141(3):478-487 [16490493.001]
  • [Cites] Mol Vis. 2006;12:159-76 [16568029.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):755-7 [16767101.001]
  • [Cites] Am J Ophthalmol. 2006 Sep;142(3):520-1 [16935612.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3919-26 [16936105.001]
  • [Cites] J Med Genet. 2007 Jan;44(1):64-8 [16825429.001]
  • [Cites] Clin Experiment Ophthalmol. 2007 Jan-Feb;35(1):99-102 [17300585.001]
  • [Cites] Exp Eye Res. 2007 Apr;84(4):680-6 [17289024.001]
  • [Cites] Hum Mutat. 2007 May;28(5):522-3 [17397048.001]
  • [Cites] J Med Genet. 2007 May;44(5):322-6 [17220209.001]
  • [Cites] Cornea. 2007 Aug;26(7):896-900 [17667634.001]
  • [Cites] PLoS One. 2007;2(8):e685 [17668063.001]
  • [Cites] Mol Vis. 2007;13:1327-32 [17679935.001]
  • [Cites] Mol Vis. 2007;13:1390-6 [17768377.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5007-12 [17962451.001]
  • [Cites] Br J Ophthalmol. 2007 Dec;91(12):1717-8 [18024822.001]
  • [Cites] Cornea. 2007 Dec;26(10):1267-9 [18043189.001]
  • [Cites] Cornea. 2007 Dec;26(10):1288-91 [18043197.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Jan;49(1):184-8 [18172091.001]
  • [Cites] J Refract Surg. 2008 Jan;24(1):39-45 [18269147.001]
  • [Cites] Hum Mol Genet. 2008 Mar 1;17(5):656-66 [18024964.001]
  • [Cites] Ophthalmic Genet. 2008 Mar;29(1):41-5 [18363173.001]
  • [Cites] Trans Am Ophthalmol Soc. 2007;105:616-48 [18427632.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 May;49(5):1843-9 [18436818.001]
  • [Cites] Arch Ophthalmol. 2008 May;126(5):700-8 [18474783.001]
  • [Cites] Mol Vis. 2008;14:1234-9 [18615206.001]
  • [Cites] Mol Vis. 2008;14:1277-81 [18618004.001]
  • [Cites] Mol Vis. 2008;14:1298-302 [18636123.001]
  • [Cites] Mol Vis. 2008;14:1713-8 [18806880.001]
  • [Cites] Orphanet J Rare Dis. 2008;3:28 [18922146.001]
  • [Cites] Acta Ophthalmol. 2008 Nov;86(7):758-63 [18778339.001]
  • [Cites] Mol Vis. 2009;15:319-25 [19204788.001]
  • [Cites] Cornea. 2008 Dec;27 Suppl 2:S1-83 [19337156.001]
  • [Cites] Acta Ophthalmol. 2009 Sep;87(6):659-65 [18700883.001]
  • [Cites] Am J Pathol. 1967 Mar;50(3):371-99 [4163628.001]
  • [Cites] Acta Ophthalmol (Copenh). 1967;45(6):829-36 [5300718.001]
  • [Cites] Klin Monbl Augenheilkd. 1967;150(6):862-74 [5301630.001]
  • [Cites] Acta Ophthalmol (Copenh). 1968;46(3):477-85 [5304426.001]
  • [Cites] Trans Am Ophthalmol Soc. 1968;66:530-635 [4181022.001]
  • [Cites] Br J Ophthalmol. 1969 Sep;53(9):577-91 [4900143.001]
  • [Cites] Ann Clin Res. 1969 Dec;1(4):314-24 [4313418.001]
  • [Cites] Invest Ophthalmol. 1971 Feb;10(2):89-99 [4925768.001]
  • [Cites] Am J Ophthalmol. 1971 Nov;72(5):879-87 [4940980.001]
  • [Cites] Ophthalmologica. 1972;165(1):15-37 [4115977.001]
  • [Cites] Am J Ophthalmol. 1973 Dec;76(6):967-71 [4543367.001]
  • [Cites] Am J Ophthalmol. 1974 May;77(5):701-10 [4596033.001]
  • [Cites] Arch Ophthalmol. 1975 Apr;93(4):259-63 [1078975.001]
  • [Cites] Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1975;194(1):1-9 [1079116.001]
  • [Cites] Am J Ophthalmol. 1977 Feb;83(2):213-8 [299986.001]
  • (PMID = 19236704.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / R01 EY008249; United States / NEI NIH HHS / EY / R01 EY012712; United States / NEI NIH HHS / EY / R01 EY016514; United States / NEI NIH HHS / EY / R01 EY08249
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Number-of-references] 152
  • [Other-IDs] NLM/ PMC2695576
  •  go-up   go-down


16. Lee YS, Kim SY, Kwon CW, Song HG, Lee YK, Kim HJ, Zang DY: Two cases of systemic capillary leak syndrome that were treated with pentastarch. Korean J Intern Med; 2007 Jun;22(2):130-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic capillary leak syndrome (SCLS) is a condition that's caused by the shift of fluid and protein from the intravascular space to the interstitial space as a result of repetitive episodes of capillary hyperpermeability.
  • The pathogenesis of SCLS is still unclear, but there's recently been a report showing this syndrome in association with monoclonal gammopathy.
  • This syndrome can be a fatal disease because cardiovascular collapse can occur in the initial capillary leak phase.
  • Considering that this disease is self-limiting, conservative treatment in the acute phase is believed to be very important.
  • [MeSH-major] Capillary Leak Syndrome / drug therapy. Hydroxyethyl Starch Derivatives / therapeutic use. Plasma Substitutes / therapeutic use

  • Genetic Alliance. consumer health - Systemic capillary leak syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Intern Med. 2000 Jun;247(6):731-5 [10886496.001]
  • [Cites] Chest. 2001 Oct;120(4):1301-8 [11591575.001]
  • [Cites] Crit Care Med. 2003 Aug;31(8 Suppl):S502-11 [12907879.001]
  • [Cites] Acta Haematol. 2005;113(2):150-1 [15802896.001]
  • [Cites] Am J Med. 1997 Dec;103(6):514-9 [9428835.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):905-9 [10375339.001]
  • [Cites] Am J Med. 1960 Aug;29:193-216 [13693909.001]
  • [Cites] Medicine (Baltimore). 1977 May;56(3):225-39 [870792.001]
  • (PMID = 17616032.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Hydroxyethyl Starch Derivatives; 0 / Plasma Substitutes
  • [Other-IDs] NLM/ PMC2687610
  •  go-up   go-down


17. McMaster ML, Csako G: Protein electrophoresis, immunoelectrophoresis and immunofixation electrophoresis as predictors for high-risk phenotype in familial Waldenström macroglobulinemia. Int J Cancer; 2008 Mar 1;122(5):1183-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Protein electrophoresis is used for the detection, evaluation and follow-up of monoclonal gammopathy (MG) conditions such as Waldenström macroglobulinemia (WM).
  • Immunofixation electrophoresis (IFE) is currently the most common method for isotyping of monoclonal gammopathy because of its superior sensitivity relative to immunoelectrophoresis (IEP).
  • We designed a study to evaluate the clinicobiological relevance of small monoclonal bands detected by serum protein electrophoresis, IEP, and IFE.
  • Serum protein electrophoresis, IEP, and IFE were used to evaluate possible monoclonal gammopathy in 46 members (29 relatives and 17 nonbloodline spouses) from 3 families with multiple cases of WM.
  • IFE identified small monoclonal bands initially missed by IEP in 5 individuals (2 blood relatives, 3 spouses) among 46 study participants.
  • Twenty-three individuals, including the 2 blood relatives and 2 of 3 spouses with monoclonal gammopathy, were then followed for a median of 17 years (range, 13-25).
  • The monoclonal gammopathy progressed in the 2 relatives but disappeared in the spouses, and new IgM MG developed in 2 additional relatives with a prior history of IgM polyclonal gammopathy.
  • Small monoclonal bands detected by IFE in a familial context may be biologically meaningful, both as phenotypic biomarkers and possibly as predictors of high risk for WM.
  • [MeSH-major] Blood Protein Electrophoresis. Electrophoresis, Agar Gel. Immunoelectrophoresis. Waldenstrom Macroglobulinemia / blood. Waldenstrom Macroglobulinemia / diagnosis

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17990319.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M
  •  go-up   go-down


18. Miyazaki D, Yazaki M, Gono T, Kametani F, Tsuchiya A, Matsuda M, Takenaka Y, Hosh Y 2nd, Ikeda S: AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: a case report. Amyloid; 2008 Jun;15(2):125-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 67-year-old male patient who suffered from nephrotic syndrome and progressive renal dysfunction with monoclonal gammopathy (IgMkappa).
  • Biochemical analysis of the deposited amyloid fibrils in gastroduodenal mucosa revealed that the amyloid fibrils were composed of an immunoglobulin heavy chain variable region (VH) fragment belonging to the VH1 subgroup, and a diagnosis of AH amyloidosis was made.
  • In our institute, three patients with AH amyloidosis including the present one have been identified during the past 2 years, so AH amyloidosis seems to be by no means a rare disorder.

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18484339.001).
  • [ISSN] 1744-2818
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region
  • [Number-of-references] 11
  •  go-up   go-down


19. Racanelli V, Leone P, Frassanito MA, Brunetti C, Perosa F, Ferrone S, Dammacco F: Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood; 2010 Feb 11;115(6):1185-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma.
  • We hypothesized that progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) reflects the escape of transformed plasma cells from T-cell recognition because of impaired antigen processing-presenting machinery (APM).
  • We studied plasma cells and CD8(+) T cells from bone marrow of 20 MGUS patients, 20 MM patients, and 10 control patients.
  • Immunofluorescence and flow cytometry revealed significantly different patterns of APM component expression in plasma cells from the 3 groups.
  • MGUS samples had intermediate percentages of stained cells but molecular equivalents of soluble fluorochrome similar to control patients.
  • Cytotoxicity assays demonstrated that MGUS CD8(+) T cells lysed autologous transformed plasma cells more than MM CD8(+) T cells did.
  • MGUS progression correlated directly with calnexin, calreticulin, and tapasin and indirectly with delta, LMP2, and LMP10 expression levels; MM disease status did not correlate with APM levels.
  • APM changes may allow transformed plasma cells to elude immunesurveillance in the MGUS-MM pathogenetic sequence.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1988 Mar 3;332(6159):83-5 [3258060.001]
  • [Cites] J Immunol. 1983 May;130(5):2471-8 [6187860.001]
  • [Cites] Cell Immunol. 1995 May;162(2):248-55 [7743552.001]
  • [Cites] Curr Opin Immunol. 1999 Feb;11(1):76-81 [10047537.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2132-4 [15561890.001]
  • [Cites] J Immunol Methods. 2005 Apr;299(1-2):139-51 [15896802.001]
  • [Cites] Tissue Antigens. 2005 Sep;66(3):185-94 [16101829.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2100-5 [17095627.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5387-98 [17911625.001]
  • [Cites] Cancer. 2008 Feb 1;112(3):659-70 [18181098.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2962-72 [18332230.001]
  • [Cites] Oncogene. 2008 Oct 6;27(45):5869-85 [18836468.001]
  • [Cites] Eur J Immunol. 2009 Jan;39(1):56-66 [19065646.001]
  • [Cites] J Immunol. 2000 Sep 15;165(6):3275-83 [10975844.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Mar;2(3):179-87 [11265247.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1745-57 [11861292.001]
  • [Cites] Blood. 2002 May 1;99(9):3280-5 [11964294.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):175-87 [11990854.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1417-24 [12149226.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5483-95 [12154409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13009-13 [12235374.001]
  • [Cites] Curr Opin Immunol. 2003 Feb;15(1):66-8 [12495735.001]
  • [Cites] Curr Opin Immunol. 2003 Feb;15(1):75-81 [12495737.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] J Exp Med. 2003 Jun 16;197(12):1667-76 [12796469.001]
  • [Cites] Tissue Antigens. 2003 Nov;62(5):385-93 [14617045.001]
  • [Cites] J Exp Med. 2003 Dec 1;198(11):1753-7 [14638846.001]
  • [Cites] J Exp Med. 2003 Dec 1;198(11):1623-6 [14638849.001]
  • [Cites] J Immunol. 2004 Aug 1;173(3):1526-34 [15265880.001]
  • [Cites] Transplantation. 1982 Jul;34(1):18-23 [6181590.001]
  • [Cites] Clin Exp Immunol. 1988 Aug;73(2):214-8 [3263229.001]
  • (PMID = 20008301.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113861; United States / NCI NIH HHS / CA / R01 CA110249; United States / NCI NIH HHS / CA / CA109688,; United States / NCI NIH HHS / CA / CA110249; United States / NCI NIH HHS / CA / P01 CA109688; United States / NCI NIH HHS / CA / R01 CA113861
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / RNA, Messenger; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2826230
  •  go-up   go-down


20. Ocio EM, Mateo G, Vidriales B, Lopez-Berges MC, Garcia-Sanz R, Hernandez JM, Orfao A, San Miguel JF: Cell cycle analysis of Waldenstrom's macroglobulinemia. Clin Lymphoma; 2005 Mar;5(4):250-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle analysis of Waldenstrom's macroglobulinemia.
  • Little is known about the DNA cell content and cell cycle characteristics of immunoglobulin (Ig) M monoclonal gammopathies.
  • The autonomous clone appears to be rather heterogeneous, from mature B lymphocytes to plasma cells (PCs).
  • We have evaluated the DNA cell content of 27 patients with IgM monoclonal gammopathies: 18 of them had Waldenstrom's macroglobulinemia (WM), and 9 were diagnosed with IgM-monoclonal gammopathy of undetermined significance (MGUS).
  • To specifically analyze the cell cycle of the B lymphocyte and PC populations, we used a flow-cytometric double-staining technique with CD19/CD20/CD22 propidium iodide for B lymphocytes and CD38/CD138 propidium iodide for PCs.
  • In 26 of 27 patients, both subsets of tumor cells (B lymphocyte and PC) showed a diploid DNA cell content (DNA index, 1).
  • No differences were observed when comparing the proliferative activity of WM with that of IgM MGUS (median, 1.7% vs. 2.2%, respectively).
  • Cell cycle characteristics of PCs were simultaneously evaluated in 9 patients, with 1.8% cells in S phase or G2/M phase.
  • In summary, the cell cycle analysis showed that IgM monoclonal gammopathies are low-proliferative disorders, with a DNA ploidy pattern (diploid) clearly different from that of multiple myeloma.
  • [MeSH-major] Cell Cycle. DNA / analysis. Immunoglobulin M / immunology. Ploidies. Waldenstrom Macroglobulinemia / genetics. Waldenstrom Macroglobulinemia / physiopathology
  • [MeSH-minor] Cell Proliferation. Flow Cytometry. Humans. Multiple Myeloma / genetics. Multiple Myeloma / physiopathology. Plasma Cells / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794858.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M; 9007-49-2 / DNA
  •  go-up   go-down


21. Eby C: Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol; 2009 Apr;145(2):151-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias.
  • Unexpectedly high rates of venous thromboembolic events (VTE) concurrent with the introduction of highly effective immune modulating drugs thalidomide and lenolidomide for treatment of multiple myeloma have focused attention on the incidence and underlying pathophysiology of VTE in patients with plasma cell dyscrasias, and on thromboprophylaxis approaches.
  • While bleeding complications are relatively uncommon in patients with lymphoproliferative disorders, acquired von Willebrand syndrome, typically occurring in patients with monoclonal gammopathy of unknown significance, and acquired coagulopathies associated with primary amyloidosis can present with haemorrhagic complications and both are challenging to manage.
  • This review highlights these important haemostasis-related complications of plasma cell dyscrasias and provides an overview of other uncommon bleeding and thrombotic events that can affect diagnostic and therapeutic management of clonal plasma cell disorders.

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210509.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Immunosuppressive Agents; 0 / Protease Inhibitors; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib
  • [Number-of-references] 145
  •  go-up   go-down


22. Pérez-Persona E, Vidriales MB, Mateo G, García-Sanz R, Mateos MV, de Coca AG, Galende J, Martín-Nuñez G, Alonso JM, de Las Heras N, Hernández JM, Martín A, López-Berges C, Orfao A, San Miguel JF: New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood; 2007 Oct 1;110(7):2586-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
  • Monoclonal gammopathy of uncertain significance (MGUS) and smoldering multiple myeloma (SMM) are plasma cell disorders with a risk of progression of approximately 1% and 10% per year, respectively.
  • We have previously shown that the proportion of bone marrow (BM) aberrant plasma cells (aPCs) within the BMPC compartment (aPC/BMPC) as assessed by flow cytometry (FC) contributes to differential diagnosis between MGUS and multiple myloma (MM).
  • The goal of the present study was to investigate this parameter as a marker for risk of progression in MGUS (n = 407) and SMM (n = 93).
  • Patients with a marked predominance of aPCs/BMPC (> or = 95%) at diagnosis displayed a significantly higher risk of progression both in MGUS and SMM (P< .001).
  • Multivariate analysis for progression-free survival (PFS) selected the percentage aPC/BMPC (> or = 95%) as the most important independent variable, together with DNA aneuploidy and immunoparesis, for MGUS and SMM, respectively.
  • Using these independent variables, we have identified 3 risk categories in MGUS (PFS at 5 years of 2%, 10%, and 46%, respectively; P< .001) and SMM patients (PFS at 5 years of 4%, 46%, and 72%, respectively; P < .001).
  • Our results show that multiparameter FC evaluation of BMPC at diagnosis is a valuable tool that could help to individualize the follow-up strategy for MGUS and SMM patients.
  • [MeSH-major] Bone Marrow Cells / pathology. Multiple Myeloma / classification. Multiple Myeloma / pathology. Paraproteinemias / classification. Paraproteinemias / pathology. Plasma Cells / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Flow Cytometry. Humans. Male. Middle Aged. Phenotype. Risk Factors


23. Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, Jayabalan D, Niesvizky R, Jagannath S, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ: Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun; 2010 Jan 29;10:4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The type I melanoma antigen gene (MAGE) proteins CT7 (MAGE-C1) and MAGE-A3 are commonly expressed in multiple myeloma (MM), and their expression correlates with increased plasma cell proliferation and poor clinical outcome.
  • We analyzed cellular and humoral immune responses against CTAgs in patients with plasma cell dyscrasias: MM, monoclonal gammopathy of undetermined significance (MGUS), and Waldenström's macroglobulinemia (WM).
  • [MeSH-major] Antigens, Neoplasm / immunology. Immunity, Cellular. Immunity, Humoral. Multiple Myeloma / immunology. Neoplasm Proteins / immunology
  • [MeSH-minor] Aged. Cell Separation. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Fluorescent Antibody Technique. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4760-5 [10781081.001]
  • [Cites] J Immunol. 2007 Mar 1;178(5):3307-15 [17312182.001]
  • [Cites] Nat Biotechnol. 2002 Feb;20(2):143-8 [11821859.001]
  • [Cites] Immunol Rev. 2002 Oct;188:22-32 [12445278.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2982-9 [17409404.001]
  • [Cites] J Exp Med. 2007 Apr 16;204(4):831-40 [17389240.001]
  • [Cites] Cancer Immunol Immunother. 2007 Oct;56(10):1577-87 [17361438.001]
  • [Cites] J Immunother. 2007 Nov-Dec;30(8):847-54 [18049337.001]
  • [Cites] Cancer Immun. 2008;8:2 [18237105.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2962-72 [18332230.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1646-8 [18323799.001]
  • [Cites] Cancer Immunol Immunother. 2009 Mar;58(3):325-38 [18663444.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1343-52 [19190130.001]
  • [Cites] Methods Mol Biol. 2009;520:11-9 [19381944.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4499-507 [19509133.001]
  • [Cites] Vaccine. 2002 Dec 19;20 Suppl 4:A8-A22 [12477423.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):842-8 [12786794.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2046-54 [14630810.001]
  • [Cites] N Engl J Med. 1975 Oct 30;293(18):887-92 [1080834.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(8):2804-8 [2784858.001]
  • [Cites] N Engl J Med. 1991 Oct 31;325(18):1267-73 [1922221.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1643-7 [1840703.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2787-93 [8839877.001]
  • [Cites] Methods Mol Med. 2005;109:97-112 [15585916.001]
  • [Cites] Blood. 2005 Jul 1;106(1):167-74 [15761016.001]
  • [Cites] Cell Mol Life Sci. 2005 Aug;62(15):1755-62 [16003494.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4217-24 [16144804.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11345-53 [16357141.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1963-9 [16249391.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1103-12 [17023585.001]
  • [Cites] J Clin Pathol. 2001 Sep;54(9):669-74 [11533070.001]
  • (PMID = 20108890.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K01 CA115917; United States / NCI NIH HHS / CA / K01 CA115917-04; United States / NCI NIH HHS / CA / NCI K01-CA115917
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MAGEA3 protein, human; 0 / MAGEC1 protein, human; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS227264; NLM/ PMC2926649
  •  go-up   go-down


24. Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD Jr, Zhan F: Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood; 2010 Jan 7;115(1):61-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.
  • Tumor-bone marrow microenvironment interactions in multiple myeloma (MM) are documented to play crucial roles in plasma-cell growth/survival.
  • In vitro coculture of MM cells with osteoclasts supported cell survival and significantly down-regulated JUN expression.
  • JUN expression in myeloma cells from late-stage and high-risk MM was significantly lower than in plasma cells from healthy donors, monoclonal gammopathy of undetermined significance, smoldering MM, and low-risk MM; patients with low-JUN-expressing MM cells had earlier disease-related deaths.
  • JUN overexpression in MM cells induced cell death and growth inhibition and up-regulated expression of early growth response protein 1 (EGR-1), whose low expression also carried unfavorable clinical implications.
  • EGR-1 knockdown in MM cells abrogated JUN overexpression-induced MM cell death and growth inhibition, indicating that EGR-1 acts directly downstream of JUN.
  • JUN modulates myeloma cell apoptosis through interacting with EGR-1, which down-regulates Survivin and triggers caspase signaling.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2008 Jan 3;27(1):98-106 [17599039.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Dec;20(4):761-81 [18070718.001]
  • [Cites] Prostate. 2008 Mar 1;68(4):427-41 [18196534.001]
  • [Cites] J Biol Chem. 2008 May 2;283(18):12120-8 [18281687.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2720-5 [18433012.001]
  • [Cites] Cancer Sci. 2008 Sep;99(9):1709-14 [18537980.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1909-16 [18650844.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4235-46 [18337559.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(2):575-82 [10611236.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3560-8 [11071655.001]
  • [Cites] J Neurosci. 2001 Jan 1;21(1):45-52 [11150318.001]
  • [Cites] Biochemistry. 2001 Jan 30;40(4):1117-23 [11170436.001]
  • [Cites] Leukemia. 2001 Mar;15(3):391-7 [11237062.001]
  • [Cites] Nat Cell Biol. 2001 May;3(5):453-9 [11331872.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2390-400 [11402335.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):271-8 [11466679.001]
  • [Cites] J Neurosci. 2001 Aug 15;21(16):5893-901 [11487612.001]
  • [Cites] J Neurol Sci. 2001 Aug 15;189(1-2):83-91 [11535237.001]
  • [Cites] Nat Cell Biol. 2001 Dec;3(12):1124-8 [11781575.001]
  • [Cites] J Cell Biochem. 2002;85(2):381-91 [11948693.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):91-7 [12085263.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):31364-72 [12072430.001]
  • [Cites] J Cell Physiol. 2002 Dec;193(3):287-92 [12384981.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1530-4 [12393500.001]
  • [Cites] Hematol J. 2003;4(5):310-4 [14502254.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):43-52 [14965266.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2016-23 [15026338.001]
  • [Cites] N Engl J Med. 2004 Oct 28;351(18):1860-73 [15509819.001]
  • [Cites] Cell. 1987 Jun 19;49(6):729-39 [3034432.001]
  • [Cites] Cell. 1988 Apr 8;53(1):37-43 [3127059.001]
  • [Cites] Cell. 1988 Dec 2;55(5):875-85 [3142689.001]
  • [Cites] J Biol Chem. 1995 Jul 14;270(28):16483-6 [7622446.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):20131-8 [9242687.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Cancer Gene Ther. 1998 Jan-Feb;5(1):3-28 [9476963.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):925-30 [15999367.001]
  • [Cites] Cancer Sci. 2006 Jun;97(6):540-5 [16734734.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6708-13 [16818645.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(11):1564-73 [16765041.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2020-8 [16728703.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1154-60 [16855375.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1680-8 [17308109.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2276-84 [17105813.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3827-34 [17440097.001]
  • [Cites] Blood. 2007 May 15;109(10):4470-7 [17255354.001]
  • [Cites] Br J Haematol. 2007 Jun;137(6):530-6 [17489983.001]
  • [Cites] Br J Haematol. 2007 Jul;138(2):176-85 [17593024.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15759-64 [17893331.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1278-87 [18027854.001]
  • (PMID = 19837979.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA055819; United States / NCI NIH HHS / CA / R01 CA113992; United States / NCI NIH HHS / CA / P01 CA55819
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Boronic Acids; 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Proto-Oncogene Proteins c-jun; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Other-IDs] NLM/ PMC2803692
  •  go-up   go-down


25. Gabrea A, Leif Bergsagel P, Michael Kuehl W: Distinguishing primary and secondary translocations in multiple myeloma. DNA Repair (Amst); 2006 Sep 8;5(9-10):1225-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple myeloma (MM) is a malignant post-germinal center tumor of somatically-mutated, isotype-switched plasma cells that accumulate in the bone marrow.
  • It often is preceded by a stable pre-malignant tumor called monoclonal gammopathy of undetermined significance (MGUS), which can sporadically progress to MM.
  • Five recurrent primary translocations involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 have been identified in MGUS and MM tumors.
  • A MYC gene is dysregulated by complex translocations and insertions as a very late event during the progression of MM tumors.
  • Since the IgH switch recombination and somatic hypermutation mechanism are turned off in plasma cells and plasma cell tumors, the MYC rearrangements are thought to be mediated by unknown mechanisms that contribute to structural genomic instability in all kinds of tumors.
  • It is hypothesized that secondary translocations not involving a MYC gene can occur at any stage of tumorigenesis, including in pre-malignant MGUS tumor cells.
  • [MeSH-minor] Burkitt Lymphoma / genetics. Chromosome Breakage. Humans. Immunoglobulins / genetics. Lymphoma, B-Cell / genetics. Models, Genetic. Plasmacytoma / genetics


26. Nakamura Y, Sato Y, Ito Y, Maeda T, Takahashi N, Kawai N, Jinnai I, Bessho M, Kinoshita S, Yamamoto T: [POEMS syndrome presenting with transient immunoglobulin isotype switching after successful treatment with autologous peripheral blood stem cell transplantation]. Rinsho Ketsueki; 2007 Aug;48(8):642-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [POEMS syndrome presenting with transient immunoglobulin isotype switching after successful treatment with autologous peripheral blood stem cell transplantation].
  • Based on the existence of monoclonal gammopathy of the IgG-lamda type, a slight increase of plasma cells in the bone marrow, and an elevated level of serum vascular endothelial growth factor (VEGF), the diagnosis of POEMS syndrome was made.
  • After peripheral blood stem cell collection by etoposide and G-CSF, the patient received high dose melphalan (200 mg/m2) therapy supported by autologous peripheral blood stem cell transplantation (autoPBSCT).
  • After high-dose chemotherapy with autoPBSCT, the serum VEGF level normalized and the monoclonal IgG-lamda, disappeared.
  • After the autoPBSCT, monoclonal IgG-kappa, protein was detected transiently in serum.
  • The new monoclonal immunoglobulin was considered to be due to normal immune reconstitution after myeloablation rather than alteration of the abnormal plasma cell clone, similarly as oligoclonal immunoglobulins occur in multiple myeloma after autoPBSCT.
  • [MeSH-major] POEMS Syndrome / immunology. POEMS Syndrome / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - POEMS syndrome.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867301.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


27. Argyriou AA: Molecularly targeted therapies for dysimmune neuropathies. Mol Med; 2009 Jul-Aug;15(7-8):283-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conventional treatment options, including corticosteroids, intravenous immunoglobulin, or plasma exchange, often fail to treat dysimmune neuropathies, such as chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and monoclonal gammopathy with its subtypes.
  • Currently, several monoclonal antibodies (MAbs) have been tested in open-label small-sized studies or even in single cases so as to establish future directions in the therapy of diseases of the peripheral nervous system (PNS).
  • Rituximab, an MAb targeting against the B cell surface membrane protein CD20, is the most widely used and promising MAb for the treatment of dysimmune neuropathies, especially for those in which immunoglobulin M (IgM) autoantibodies are pathogenetically involved.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Autoimmune Diseases of the Nervous System / therapy. Drug Delivery Systems / methods. Immunologic Factors / therapeutic use. Polyneuropathies / therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / therapeutic use. Bevacizumab. Etanercept. Humans. Immunoglobulin G / therapeutic use. Receptors, Tumor Necrosis Factor / therapeutic use. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. Etanercept .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2003 Dec;62(12):1230-3 [14644867.001]
  • [Cites] Acta Neurol Scand. 2005 Aug;112(2):115-25 [16008538.001]
  • [Cites] Drug Saf. 2004;27(5):307-24 [15061685.001]
  • [Cites] Neurology. 2004 Aug 24;63(4):730-2 [15326255.001]
  • [Cites] Muscle Nerve. 1998 Nov;21(11):1390-7 [9771661.001]
  • [Cites] J Neurol Sci. 1999 Feb 1;163(1):47-52 [10223410.001]
  • [Cites] Eur J Neurol. 2004 Nov;11(11):788 [15525302.001]
  • [Cites] Neurology. 2004 Dec 14;63(11):2178-9 [15596777.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1343-56 [15800230.001]
  • [Cites] Lancet Neurol. 2005 May;4(5):309-19 [15847844.001]
  • [Cites] J Intern Med. 2005 Jun;257(6):540-8 [15910558.001]
  • [Cites] J Peripher Nerv Syst. 2005 Jun;10(2):113-27 [15958124.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1135 [16033956.001]
  • [Cites] Muscle Nerve. 2005 Sep;32(3):378-9 [15986418.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1410-4 [16170087.001]
  • [Cites] J Peripher Nerv Syst. 2006 Mar;11(1):9-19 [16519778.001]
  • [Cites] Neurology. 2006 Mar 14;66(5):742-4 [16534115.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):800-2 [16705208.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4972-3; author reply 4973-4 [16754779.001]
  • [Cites] J Rheumatol. 2006 Jun;33(6):1197-8 [16755669.001]
  • [Cites] Leuk Lymphoma. 2006 May;47(5):859-64 [16753870.001]
  • [Cites] Clin Infect Dis. 2006 Jul 1;43(1):16-24 [16758413.001]
  • [Cites] Muscle Nerve. 2007 Jan;35(1):66-9 [16967492.001]
  • [Cites] Neurol Clin. 2007 Feb;25(1):89-113 [17324722.001]
  • [Cites] Intern Med. 2007;46(6):311-3 [17380000.001]
  • [Cites] J Neurol Sci. 2007 May 15;256(1-2):100-2 [17382963.001]
  • [Cites] J Peripher Nerv Syst. 2007 Jun;12(2):102-7 [17565535.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1438-9 [18024383.001]
  • [Cites] Rheumatol Int. 2008 Mar;28(5):503-6 [17924113.001]
  • [Cites] Eur J Haematol. 2008 May;80(5):381-5 [18221389.001]
  • [Cites] Neurology. 2008 Jun 3;70(23):2252-60 [18519875.001]
  • [Cites] J Peripher Nerv Syst. 2008 Jun;13(2):136-47 [18601658.001]
  • [Cites] Muscle Nerve. 2008 Aug;38(2):1076-7 [18642360.001]
  • [Cites] Neurology. 2001 Mar 13;56(5):666-9 [11245723.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):2-9 [11842383.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):105-12 [11842397.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(1):CD002827 [12535440.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):485-9 [12640069.001]
  • [Cites] Blood. 2003 May 15;101(10):3818-26 [12506023.001]
  • [Cites] Blood. 2003 May 15;101(10):3827-34 [12560225.001]
  • [Cites] J Neurol Sci. 2003 Jun 15;210(1-2):19-21 [12736082.001]
  • [Cites] Neurology. 2003 Nov 11;61(9):1307-8 [14610153.001]
  • [Cites] Muscle Nerve. 2003 May;27(5):611-5 [12707982.001]
  • [Cites] Neurology. 2008 Nov 18;71(21):1742-4 [19015493.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2256-62 [19052972.001]
  • [Cites] Ann Neurol. 2009 Mar;65(3):286-93 [19334068.001]
  • [Cites] J Peripher Nerv Syst. 2003 Dec;8(4):282-4 [14641652.001]
  • (PMID = 19593413.001).
  • [ISSN] 1528-3658
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Immunoglobulin G; 0 / Immunologic Factors; 0 / Receptors, Tumor Necrosis Factor; 2S9ZZM9Q9V / Bevacizumab; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab; OP401G7OJC / Etanercept
  • [Number-of-references] 48
  • [Other-IDs] NLM/ PMC2707512
  •  go-up   go-down


28. Kyle RA, Rajkumar SV: Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol; 2007 Dec;139(5):730-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
  • Monoclonal gammopathy of undetermined significance (MGUS) is characterized by a serum monoclonal protein <30 g/l, <10% plasma cells in the bone marrow, and absence of end-organ damage (CRAB-hypercalcaemia, renal insufficiency, anaemia, or bone lesions).
  • MGUS is present in 3% of persons >50 years and in 5% >70 years of age.
  • The risk of progression to multiple myeloma (MM) or a related disorder is 1% per year.
  • Patients with risk factors consisting of an abnormal serum free light chain ratio, non-immunoglobulin G (IgG) MGUS, and an elevated serum M protein >/=15 g/l had a risk of progression at 20 years of 58%, compared with 37% with two risk factors present, 21% with one risk factor present, and 5% when none of the risk factors were present.
  • Smouldering (asymptomatic) multiple myeloma is characterized by having a serum IgG or IgA monoclonal protein of 30 g/l or higher and/or 10% or more plasma cells in the bone marrow but no evidence of end-organ damage.
  • [MeSH-major] Monoclonal Gammopathy of Undetermined Significance / etiology. Multiple Myeloma / etiology
  • [MeSH-minor] Diagnosis, Differential. Disease Progression. Humans. Prevalence. Risk Factors


29. Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK, Johnson DC, Dickens NJ, Brito JL, Else M, Gonzalez D, Ross FM, Chen-Kiang S, Davies FE, Morgan GJ: Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res; 2008 Oct 01;14(19):6033-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CDKN2C at 1p32.3 has been identified in myeloma cell lines as the potential target of the deletion.
  • EXPERIMENTAL DESIGN: We analyzed 515 cases of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and newly diagnosed multiple myeloma using fluorescence in situ hybridization (FISH) for deletions of CDKN2C.
  • RESULTS: By FISH we identified deletion of 1p32.3 (CDKN2C) in 3 of 66 MGUS (4.5%), 4 of 39 SMM (10.3%), and 55 of 369 multiple myeloma cases (15%).
  • Cases with homozygous deletions of CDKN2C were the most proliferative myelomas, defined by an expression-based proliferation index, consistent with its biological function as a cyclin-dependent kinase inhibitor.
  • [MeSH-minor] Aged. Cell Line, Tumor. Chromosome Mapping / methods. Disease Progression. Heterozygote. Homozygote. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Models, Genetic. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2005 Oct;44(2):194-203 [16001433.001]
  • [Cites] Br J Haematol. 2003 Jul;122(2):193-201 [12846886.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2099-103 [10602435.001]
  • [Cites] Leukemia. 2005 Feb;19(2):275-8 [15538401.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):960-9 [12648065.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2351-7 [14645011.001]
  • [Cites] Leukemia. 2003 Feb;17(2):427-36 [12592343.001]
  • [Cites] Blood. 1998 Apr 15;91(8):3007-10 [9531613.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2661-6 [15238415.001]
  • [Cites] Br J Haematol. 1997 Jan;96(1):98-102 [9012694.001]
  • [Cites] Cell Div. 2006 Oct 18;1:23 [17049078.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1650-7 [12886255.001]
  • [Cites] Oncogene. 2000 Jul 13;19(30):3434-8 [10918600.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11345-53 [16357141.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(4):1269-77 [12556487.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2A):953-9 [16619492.001]
  • [Cites] Blood. 2005 Jul 1;106(1):296-303 [15755896.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jun;19(2):124-33 [9172003.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1733-43 [16705090.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1610-7 [16826223.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2020-8 [16728703.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1634-42 [15990862.001]
  • [Cites] Immunity. 1997 Jan;6(1):47-56 [9052836.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6071-9 [16024607.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4504-11 [12947006.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2535-7 [14523465.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4542-7 [15761058.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):313-25 [16616336.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] Leukemia. 2002 Jan;16(1):127-34 [11840272.001]
  • (PMID = 18829482.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6308; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN2C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p18
  • [Other-IDs] NLM/ PMC2581792; NLM/ UKMS2612
  •  go-up   go-down


30. Scudla V, Ordeltova M, Bacovsky J, Vytrasova M, Horak P, Minarik J: The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Haematologica; 2005 Dec;90(12):1713-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma.
  • Multiple myeloma (MM) is a clonal neoplastic lymphoproliferative disease affecting terminally differentiated B cells i.e. plasma cells characterized by slow proliferation activity and different resistance to apoptosis with latent accumulation of myeloma cells in the bone marrow.
  • We compared plasma cell proliferation and apoptic indices in various phases of MM and in monoclonal gammophaty of untetermined significance.
  • [MeSH-major] Apoptosis. Paraproteinemias / pathology. Plasma Cells / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Division. Clone Cells / pathology. Disease Progression. Female. Humans. Male. Middle Aged. Mitotic Index. Multiple Myeloma / drug therapy. Multiple Myeloma / pathology. Multiple Myeloma / surgery. Peripheral Blood Stem Cell Transplantation. Transplantation, Autologous

  • Genetic Alliance. consumer health - Multiple myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330455.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


31. Lottersberger F, Panza A, Lucchini G, Longhese MP: Functional and physical interactions between yeast 14-3-3 proteins, acetyltransferases, and deacetylases in response to DNA replication perturbations. Mol Cell Biol; 2007 May;27(9):3266-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inactivation of the catalytic subunit of the histone acetyltransferase NuA4 or of its interactor Yng2, besides leading to S-phase defects and persistent checkpoint activation in the presence of genotoxic agents, is lethal for bmh mutants.
  • Conversely, the lack of the histone deacetylase subunit Rpd3 or Sin3 partially suppresses the hypersensitivity to HU of bmh mutants and restores their ability to complete DNA replication in the presence of MMS or HU.
  • These data strongly suggest that reduced acetyltransferase functionality might account for the S-phase defects of bmh mutants in the presence of genotoxic agents.
  • Consistent with a role of 14-3-3 proteins in acetyltransferase and deacetylase regulation, we find that acetylation of H3 and H4 histone tails is reduced in temperature-sensitive bmh mutants shifted to the restrictive temperature.
  • Moreover, Bmh proteins physically interact, directly or indirectly, with the Esa1 acetyltransferase throughout the cell cycle and with the Rpd3 deacetylase specifically during unperturbed S phase and after HU treatment.
  • [MeSH-minor] Cell Cycle Proteins / metabolism. Checkpoint Kinase 2. Enzyme Activation. Genome, Fungal / genetics. Intracellular Signaling Peptides and Proteins. Methyl Methanesulfonate / metabolism. Mutation / genetics. Protein Binding. Protein Subunits / genetics. Protein Subunits / metabolism. Protein-Serine-Threonine Kinases / metabolism. Repressor Proteins / genetics. Repressor Proteins / metabolism. S Phase. Saccharomyces cerevisiae Proteins / genetics. Saccharomyces cerevisiae Proteins / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism

  • Hazardous Substances Data Bank. METHYL METHANESULFONATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 2003 Nov 27;532(1-2):41-58 [14643428.001]
  • [Cites] Nature. 1998 Oct 8;395(6702):615-8 [9783589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1644-9 [14711989.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1206-13 [14647447.001]
  • [Cites] Biochem J. 2004 Apr 15;379(Pt 2):395-408 [14744259.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20194-9 [14988403.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(11):4769-80 [15143171.001]
  • [Cites] Curr Opin Genet Dev. 2004 Apr;14(2):147-54 [15196461.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34201-8 [15166223.001]
  • [Cites] EMBO J. 1992 Sep;11(9):3297-306 [1505519.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1273-6 [8122109.001]
  • [Cites] Eur J Biochem. 1995 Apr 1;229(1):45-53 [7744048.001]
  • [Cites] Cell. 1995 Sep 8;82(5):841-7 [7671311.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11539-43 [8524799.001]
  • [Cites] Science. 1996 Jan 19;271(5247):357-60 [8553072.001]
  • [Cites] Cell. 1996 Mar 22;84(6):889-97 [8601312.001]
  • [Cites] Cell. 1997 Jun 27;89(7):1055-65 [9215628.001]
  • [Cites] Cell. 1997 Dec 26;91(7):961-71 [9428519.001]
  • [Cites] Nature. 1998 Oct 8;395(6702):618-21 [9783590.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2515-26 [10082517.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23027-34 [10438470.001]
  • [Cites] EMBO J. 1999 Aug 16;18(16):4485-97 [10449414.001]
  • [Cites] Biochemistry. 1999 Oct 5;38(40):13085-93 [10529179.001]
  • [Cites] Cell. 2004 Dec 17;119(6):777-88 [15607975.001]
  • [Cites] Mol Cell. 2004 Dec 22;16(6):979-90 [15610740.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(12):4903-13 [15923609.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):25949-52 [15888442.001]
  • [Cites] Nature. 2005 Jul 14;436(7048):294-8 [16015338.001]
  • [Cites] Curr Biol. 2005 Aug 9;15(15):1364-75 [16085488.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(18):8179-90 [16135807.001]
  • [Cites] Mol Cell. 2005 Oct 28;20(2):199-211 [16246723.001]
  • [Cites] Nature. 2005 Nov 17;438(7066):379-83 [16292314.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(3):1098-108 [16428461.001]
  • [Cites] Curr Opin Cell Biol. 2006 Apr;18(2):137-44 [16487697.001]
  • [Cites] Mol Cell Biol. 2006 May;26(9):3649-58 [16612003.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):162-72 [16678438.001]
  • [Cites] Genetics. 2006 Jun;173(2):661-75 [16648583.001]
  • [Cites] Mol Cell. 2006 Jul 7;23(1):109-19 [16818235.001]
  • [Cites] Curr Biol. 2006 Jul 11;16(13):1280-9 [16815704.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):3807-16 [10805724.001]
  • [Cites] Mol Biol Cell. 2000 Jun;11(6):2103-15 [10848632.001]
  • [Cites] Yeast. 2000 Jun 30;16(9):857-60 [10861908.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7835-40 [10869435.001]
  • [Cites] Mol Cell. 2000 Jun;5(6):905-15 [10911985.001]
  • [Cites] Mol Cell. 2000 Jun;5(6):917-26 [10911986.001]
  • [Cites] Genetics. 2000 Aug;155(4):1577-91 [10924458.001]
  • [Cites] Genes Dev. 2000 Aug 15;14(16):2046-59 [10950868.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(18):6904-12 [10958686.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15397-408 [11278932.001]
  • [Cites] Nature. 2001 Aug 2;412(6846):553-7 [11484057.001]
  • [Cites] Nature. 2001 Aug 2;412(6846):557-61 [11484058.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29496-502 [12039950.001]
  • [Cites] Nature. 2002 Sep 26;419(6905):411-5 [12353039.001]
  • [Cites] Mol Cell Biol. 2002 Dec;22(23):8215-25 [12417725.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1213-22 [12453427.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1223-33 [12453428.001]
  • [Cites] Mol Cell. 2003 May;11(5):1323-36 [12769855.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(13):4522-31 [12808094.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4325-36 [12912929.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Sep;7(9):657-66 [16912715.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3561-5 [9520405.001]
  • [Cites] Genes Dev. 1998 Sep 15;12(18):2956-70 [9744871.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):329-40 [9774971.001]
  • [Cites] Genetics. 2003 Dec;165(4):1717-32 [14704161.001]
  • (PMID = 17339336.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Cell Cycle Proteins; 0 / DNA, Fungal; 0 / Intracellular Signaling Peptides and Proteins; 0 / Protein Subunits; 0 / Repressor Proteins; 0 / SIN3 protein, S cerevisiae; 0 / Saccharomyces cerevisiae Proteins; 0 / Transcription Factors; AT5C31J09G / Methyl Methanesulfonate; EC 2.3.1.48 / Esa1 protein, S cerevisiae; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / NuA4 protein, S cerevisiae; EC 2.7.1.- / RAD53 protein, S cerevisiae; EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / MEC1 protein, S cerevisiae; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.5.1.- / RPD3 protein, S cerevisiae; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ PMC1899974
  •  go-up   go-down


32. Pratt G: The evolving use of serum free light chain assays in haematology. Br J Haematol; 2008 May;141(4):413-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The new FLC assay has enabled the detection of monoclonal protein in some patients with non-secretory myeloma and amyloidosis that were previously undetectable.
  • FLC measurements are quantitative, correlating with disease activity, and are an advance in monitoring light chain only multiple myeloma, AL amyloidosis, non-secretory and oligo-secretory multiple myeloma.
  • Serum FLC concentrations also reflect the disease course in the majority of myeloma patients producing intact monoclonal immunoglobulin proteins and have been incorporated into the new response criteria.
  • An abnormal FLC ratio has been shown to be a risk factor for progression of monoclonal gammopathy of undetermined significance, smouldering myeloma and solitary plasmacytoma of bone and is prognostic in multiple myeloma.
  • [MeSH-major] Biomarkers, Tumor / blood. Immunoglobulin Light Chains / blood. Multiple Myeloma / diagnosis
  • [MeSH-minor] Hematologic Neoplasms / diagnosis. Humans. Paraproteinemias / diagnosis. Prognosis

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2008 Oct;143(1):143-5; author reply 145-6 [18671704.001]
  • (PMID = 18318757.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Light Chains
  • [Number-of-references] 72
  •  go-up   go-down


33. Weiss BM, Kuehl WM: Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Rev Hematol; 2010 Apr;3(2):165-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.
  • Monoclonal gammopathy of undetermined significance (MGUS) affects at least 3% of the population above the age of 50 and is the precursor to multiple myeloma (MM), an incurable malignancy of plasma cells.
  • Recent advances in MGUS include: an improved understanding of the pathogenesis of MGUS and its progression to MM, involving molecular events intrinsic to the malignant plasma cell as well as the microenvironment; novel techniques to assess risk for progression to MM using serum-free light-chain analysis and immunophenotyping; and a renewed interest in chemoprevention of MM.
  • In the future, continued improvement in our understanding of MGUS will lead to the development of better biomarkers for prognosis and therapies for chemoprevention of MM.
  • [MeSH-major] Multiple Myeloma / diagnosis. Paraproteinemias / diagnosis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2009 May 28;113(22):5412-7 [19179464.001]
  • [Cites] Blood. 2009 May 28;113(22):5418-22 [19234139.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6386-91 [19387005.001]
  • [Cites] Blood. 2009 Jul 23;114(4):785-90 [19179466.001]
  • [Cites] Int J Cancer. 2009 Nov 1;125(9):2147-50 [19582882.001]
  • [Cites] Clin Cancer Res. 2009 Sep 15;15(18):5917-22 [19737963.001]
  • [Cites] Br J Haematol. 2009 Oct;147(1):22-42 [19673884.001]
  • [Cites] Lancet Oncol. 2009 Oct;10(10):950-6 [19767238.001]
  • [Cites] Blood. 2009 Oct 8;114(15):3276-84 [19587378.001]
  • [Cites] Leukemia. 2009 Oct;23(10):1691-7 [19587704.001]
  • [Cites] Haematologica. 2009 Nov;94(11):1581-9 [19586941.001]
  • [Cites] Leukemia. 2009 Dec;23(12):2210-21 [19798094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):228-33 [10618400.001]
  • [Cites] Hum Mutat. 2001 Sep;18(3):212-24 [11524732.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2185-91 [11877296.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):175-87 [11990854.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2210-6 [12114422.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1417-24 [12149226.001]
  • [Cites] Clin Chem. 2002 Sep;48(9):1437-44 [12194920.001]
  • [Cites] Mayo Clin Proc. 2003 Jan;78(1):21-33 [12528874.001]
  • [Cites] Leukemia. 2003 Apr;17(4):775-9 [12682636.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Immunol Rev. 2003 Aug;194:112-39 [12846812.001]
  • [Cites] Br J Haematol. 2003 Nov;123(4):631-6 [14616966.001]
  • [Cites] J Bone Miner Res. 2004 Jan;19(1):25-30 [14753733.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1546-58 [14989251.001]
  • [Cites] Scand J Work Environ Health. 2004 Jun;30(3):215-22 [15250650.001]
  • [Cites] Blood. 2004 Aug 1;104(3):607-18 [15090448.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1159-65 [15130943.001]
  • [Cites] Br J Haematol. 2004 Sep;126(5):686-9 [15327520.001]
  • [Cites] Am J Med. 1978 May;64(5):814-26 [645746.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4762-9 [8639847.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13931-6 [8943038.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1655-65 [9626070.001]
  • [Cites] Harvey Lect. 1960-1961;56:211-31 [14004528.001]
  • [Cites] Blood. 2005 Jan 1;105(1):317-23 [15339850.001]
  • [Cites] Clin Chem. 2005 May;51(5):878-81 [15774572.001]
  • [Cites] Blood. 2005 Jul 1;106(1):296-303 [15755896.001]
  • [Cites] Blood. 2005 Aug 1;106(3):812-7 [15855274.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6333-8 [16155016.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Mayo Clin Proc. 2006 Dec;81(12):1575-8 [17165636.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2765-70 [17192542.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):393-9 [17156398.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1692-700 [17023574.001]
  • [Cites] Mayo Clin Proc. 2007 Apr;82(4):428-34 [17418070.001]
  • [Cites] J Exp Med. 2007 Apr 16;204(4):831-40 [17389240.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1993-9 [17420512.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5096-103 [17303694.001]
  • [Cites] N Engl J Med. 2007 Jun 21;356(25):2582-90 [17582068.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2586-92 [17576818.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Dec;21(6):1093-113, ix [17996590.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Sep;7(8):518-23 [18021469.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Dec;20(4):613-24 [18070709.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Dec;20(4):637-64 [18070711.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):44-54 [18172295.001]
  • [Cites] Blood. 2008 Jan 15;111(2):785-9 [17942755.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):167-80 [18242516.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2516-20 [17975015.001]
  • [Cites] Haematologica. 2008 Mar;93(3):431-8 [18268286.001]
  • [Cites] Br J Haematol. 2008 Apr;141(2):205-11 [18318761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12885-90 [18728182.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1651-7 [18668131.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3122-5 [18669874.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1933-7 [18596742.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2280-4 [18528420.001]
  • [Cites] Mayo Clin Proc. 2009 Feb;84(2):114-22 [19181644.001]
  • [Cites] Leukemia. 2009 Feb;23(2):215-24 [19020545.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1639-50 [18849487.001]
  • (PMID = 20473362.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00480363
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999; United States / Intramural NIH HHS / / ZIA SC006581-26
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS199922; NLM/ PMC2869099
  • [Keywords] NOTNLM ; MGUS / monoclonal gammopathy of undetermined significance / multiple myeloma / pathogenesis
  •  go-up   go-down


34. Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, Moehler T, Pantesco V, Moos M, Schved JF, Rossi JF, Rème T, Goldschmidt H, Klein B: Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol; 2007 Mar 1;178(5):3307-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the expression pattern of CT genes in purified MM cells (MMC) of 64 patients with newly diagnosed MM and12 patients with monoclonal gammopathy of unknown significance, in normal plasma cell and B cell samples, and in 20 MMC lines.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Gene Expression Regulation, Neoplastic. Multiple Myeloma / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312182.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines
  •  go-up   go-down


35. Mseddi-Hdiji S, Haddouk S, Ben Ayed M, Tahri N, Elloumi M, Baklouti S, Hachicha J, Krichen MS, Bahloul Z, Masmoudi H: [Monoclonal gammapathies in Tunisia: epidemiological, immunochemical and etiological analysis of 288 cases]. Pathol Biol (Paris); 2005 Feb;53(1):19-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Monoclonal gammapathies in Tunisia: epidemiological, immunochemical and etiological analysis of 288 cases].
  • [Transliterated title] Gammapathies monoclonales en Tunisie: analyse épidémiologique, immunochimique et étiologique d'une série de 288 cas.
  • From July 1992 to December 2000, 288 cases of monoclonal gammapathy (MG) were collected at the university hospital of Sfax.
  • The middle age of the patients at the time of the diagnosis was 62 years and 7 months with extremes to 18 months and 99 years and median to 64 years.
  • Among the 270 observations for which aetiology has been established, 73 were classified MG of undetermined significance (MGUS), 160 myeloma (or plasmocytoma) and 37 other malignant MG (Waldenstrom's macroglobulinemia: 13, lymphoma: 9, alpha heavy chains disease: 6, primary amyloidosis: 5, chronic lymphocytic leukaemia: 4).
  • Rheumatological affections (19.2%), infections and renal failure (10% each), haematological and autoimmune diseases (9.6% each) were pathologies most often associated with MGUS.
  • Agarose gel electrophoresis did not show a monoclonal peak in 16% of the cases.
  • IgG is even more predominant in the MGUS group (65.8%).
  • The IgA isotype counts for 20.8% of the cases in our set and the free light chains (kappa or lambda) for 13.6% of the cases whereas the IgM represents 8.7% only of the 288 cases of our set which involves three cases of IgD myeloma and six cases of biclonal gammapathy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620605.001).
  • [ISSN] 0369-8114
  • [Journal-full-title] Pathologie-biologie
  • [ISO-abbreviation] Pathol. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin M
  •  go-up   go-down


36. Bakker AJ, Mücke M: Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med; 2007;45(9):1240-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention.
  • Monoclonal gammopathy is characterized by the presence of an M-protein in serum or urine that has homogeneous structural and functional properties.
  • Examples of gammopathy interference for the analytes glucose, bilirubin, gamma-glutamyltransferase, urea and ferritin are presented.
  • Modern analyzers can detect unusual changes in absorption during the course of a reaction, and thus the formation of turbidity due to M-proteins.
  • Owing to the unique properties of each M-protein, it is impossible to protect common clinical chemistry test systems completely from gammopathy interference.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Chem Lab Med. 2009;47(5):614-5 [19278372.001]
  • (PMID = 17635066.001).
  • [ISSN] 1434-6621
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin M
  •  go-up   go-down


37. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd: Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med; 2006 Mar 30;354(13):1362-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of monoclonal gammopathy of undetermined significance.
  • BACKGROUND: The prevalence of monoclonal gammopathy of undetermined significance (MGUS), a premalignant plasma-cell disorder, among persons 50 years of age or older has not been accurately determined.
  • We used sensitive laboratory techniques to ascertain the prevalence of MGUS in a large population in a well-defined geographic area.
  • Agarose-gel electrophoresis was performed on all serum samples, and any serum sample with a discrete band of monoclonal protein or thought to have a localized band was subjected to immunofixation.
  • MGUS was identified in 694 (3.2 percent) of these persons.
  • Age-adjusted rates were higher in men than in women (4.0 percent vs. 2.7 percent, P<0.001).
  • The prevalence of MGUS was 5.3 percent among persons 70 years of age or older and 7.5 percent among those 85 years of age or older.
  • The concentration of monoclonal immunoglobulin was less than 1.0 g per deciliter in 63.5 percent and at least 2.0 g per deciliter in only 4.5 percent of 694 persons.
  • The concentration of uninvolved immunoglobulins was reduced in 27.7 percent of 447 persons tested, and 21.5 percent of 79 tested had a monoclonal urinary light chain.
  • CONCLUSIONS: Among residents of Olmsted County, Minnesota, MGUS was found in 3.2 percent of persons 50 years of age or older and 5.3 percent of persons 70 years of age or older.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Massachusetts Medical Society.
  • [CommentIn] N Engl J Med. 2006 Jun 29;354(26):2832; author reply 2832 [16807426.001]
  • (PMID = 16571879.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 107476; United States / NCI NIH HHS / CA / CA 62242
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


38. Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B: CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun; 2008 Feb 1;366(1):117-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD200 was recently described as a new prognosis factor in multiple myeloma and acute myeloid leukemia.
  • CD200 is a membrane glycoprotein that imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cell-mediated immune responses.
  • CD200 gene expression in normal or malignant human tissues or cell lines was obtained from the Oncomine Cancer Microarray database, Amazonia database and the ITTACA database.
  • We found significant overexpression of CD200 in renal carcinoma, head and neck carcinoma, testicular cancer, malignant mesothelioma, colon carcinoma, MGUS/smoldering myeloma, and in chronic lymphocytic leukemia compared to their normal cells or their tissue counterparts.
  • [MeSH-minor] Drug Design. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060862.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / antigens, CD200
  •  go-up   go-down


39. Chatterjee M, Rancso C, Stühmer T, Eckstein N, Andrulis M, Gerecke C, Lorentz H, Royer HD, Bargou RC: The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood; 2008 Apr 1;111(7):3714-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma.
  • Current knowledge about molecular mechanisms underlying disease progression and drug resistance in multiple myeloma (MM) is still limited.
  • Immunohistochemical analyses revealed that neither normal bone marrow (BM) plasma cells (PCs), premalignant PCs of patients with monoclonal gammopathy of unknown significance (MGUS), nor MM cells with a mature morphology showed expression of YB-1 in situ.
  • In contrast, YB-1 was strongly expressed in situ in normal PC precursor blasts as well as in a MM subset and in vitro in all of the evaluated MM cell lines.
  • Thus, YB-1 contributes to disease progression, survival, and drug resistance in MM and might therefore provide an attractive therapeutic target.
  • [MeSH-major] Cell Proliferation. DNA-Binding Proteins / biosynthesis. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Lymphoid Progenitor Cells / metabolism. Multiple Myeloma / metabolism. Nuclear Proteins / biosynthesis
  • [MeSH-minor] Antibiotics, Antineoplastic / pharmacology. Antibiotics, Antineoplastic / therapeutic use. Apoptosis / drug effects. Apoptosis / genetics. Bone Marrow / metabolism. Bone Marrow / pathology. Cell Line, Tumor. Doxorubicin / pharmacology. Doxorubicin / therapeutic use. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Ki-67 Antigen / genetics. Plasma Cells / metabolism. Plasma Cells / pathology. RNA, Small Interfering / genetics. Stromal Cells / metabolism. Stromal Cells / pathology. Y-Box-Binding Protein 1

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006704.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / RNA, Small Interfering; 0 / Y-Box-Binding Protein 1; 0 / YBX1 protein, human; 80168379AG / Doxorubicin
  •  go-up   go-down


40. Lynch HT, Thomé SD: Familial multiple myeloma. Blood; 2009 Jul 23;114(4):749-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this issue of Blood, there are 2 reports on the increased risk of plasma cell disorders in the first-degree relatives of patients with multiple myeloma or MGUS.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2009 Jul 23;114(4):791-5 [19182202.001]
  • [CommentOn] Blood. 2009 Jul 23;114(4):785-90 [19179466.001]
  • (PMID = 19628711.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Stewart I, Roddie C, Gill A, Clarkson A, Mirams M, Coyle L, Ward C, Clifton-Bligh P, Robinson BG, Mason RS, Clifton-Bligh RJ: Elevated serum FGF23 concentrations in plasma cell dyscrasias. Bone; 2006 Aug;39(2):369-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated serum FGF23 concentrations in plasma cell dyscrasias.
  • Fibroblast growth factor 23 (FGF23) is now recognized as a key regulator of phosphate metabolism.
  • Hypophosphatemic osteomalacia more rarely occurs in non-mesenchymal tumors.
  • We identified elevated serum FGF23 levels in one patient with chronic lymphatic leukemia (CLL) and hypophosphatemia, prompting us to examine FGF23 concentrations in other patients with B-cell neoplasms.
  • FGF23 levels were elevated in several patients with myeloma and monoclonal gammopathy of undetermined significance (MGUS), and were significantly associated with serum paraprotein and beta-2 microglobulin concentrations in these patients.
  • Malignant plasma cells in bone marrow trephines from patients with myeloma showed cytoplasmic expression of FGF23, similar to the cytoplasmic localization of FGF23 already described in mesenchymal tumors associated with oncogenic osteomalacia.
  • We suggest that the relationship between FGF23 and skeletal disease associated with plasma cell dyscrasias deserves further study.
  • [MeSH-major] Fibroblast Growth Factors / blood. Plasma Cells / pathology
  • [MeSH-minor] Aged. Calcium / blood. Fatal Outcome. Female. Humans. Hypophosphatemia / blood. Immunohistochemistry. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Osteomalacia / blood. Phosphates / blood. beta 2-Microglobulin / blood

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644301.001).
  • [ISSN] 8756-3282
  • [Journal-full-title] Bone
  • [ISO-abbreviation] Bone
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphates; 0 / beta 2-Microglobulin; 0 / fibroblast growth factor 23; 62031-54-3 / Fibroblast Growth Factors; SY7Q814VUP / Calcium
  •  go-up   go-down


42. Koski AM, Sikiö A, Forslund T: Teriparatide treatment complicated by malignant myeloma. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case with monoclonal gammopathy of uncertain significance (MGUS) who developed malignant myeloma after teriparatide treatment and we suggest that in addition to malignant myeloma and smouldering myeloma, MGUS should also be considered contraindicated for teriparatide treatment.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. TERIPARATIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3332-6 [15240611.001]
  • [Cites] Br Med J. 1980 Jun 7;280(6228):1340-4 [6992932.001]
  • [Cites] Rev Rhum Engl Ed. 1996 Jul-Sep;63(7-8):502-3 [8896065.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):688-703 [15769903.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2765-70 [17192542.001]
  • [Cites] N Engl J Med. 2001 May 10;344(19):1434-41 [11346808.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):916-25 [11159865.001]
  • [Cites] Toxicol Pathol. 2002 May-Jun;30(3):312-21 [12051548.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1655-65 [9626070.001]
  • (PMID = 22767690.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 10T9CSU89I / Teriparatide
  • [Other-IDs] NLM/ PMC3027506
  •  go-up   go-down


43. Fernández de Larrea C, Rovira M, Mascaró JM Jr, Torras A, Solé M, Lloreta J, Serra N, Cibeira MT, Bladé J: Generalized cutis laxa and fibrillar glomerulopathy resulting from IgG Deposition in IgG-lambda Monoclonal Gammopathy: pulmonary hemorrhage during stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy. Eur J Haematol; 2009 Feb;82(2):154-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalized cutis laxa and fibrillar glomerulopathy resulting from IgG Deposition in IgG-lambda Monoclonal Gammopathy: pulmonary hemorrhage during stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy.
  • The case of a 52-years-old man with generalized acquired cutis laxa associated with IgG-lambda monoclonal gammopathy and nephrotic syndrome with renal failure (due to fibrillar glomerulopathy resulting from IgG deposition) is reported.
  • A peripheral blood autologous stem cell transplant was planned, but the procedure was complicated by severe pulmonary hemorrhage during stem cells mobilization with granulocyte colony-stimulating factor (G-CSF).
  • Finally, the complete hematological response with the disappearance of the toxic M-protein allows the possibility of a long-term benefit with a kidney transplant followed by an autologous bone marrow transplant.

  • Genetic Alliance. consumer health - Cutis Laxa.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018863.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Immunoglobulin G; 0 / Pyrazines; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


44. Zheng JM, Chen S, Zhang WQ, Pan XZ, Zhu HX, Jiang WM: [Misdiagnosis of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome: a case report]. Zhonghua Gan Zang Bing Za Zhi; 2007 Aug;15(8):626-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Misdiagnosis of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome: a case report].
  • [MeSH-major] Diagnostic Errors. POEMS Syndrome / diagnosis
  • [MeSH-minor] Ascites / complications. Ascites / diagnosis. Humans. Liver Cirrhosis / complications. Liver Cirrhosis / diagnosis. Male. Middle Aged

  • Genetic Alliance. consumer health - POEMS syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711642.001).
  • [ISSN] 1007-3418
  • [Journal-full-title] Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  • [ISO-abbreviation] Zhonghua Gan Zang Bing Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


45. Silverman BA, Ku M, Kapur P, Schneider AT: Monoclonal gammopathy in association with allergic disorders of the skin and respiratory tract. Allergy Asthma Proc; 2006 Mar-Apr;27(2):130-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal gammopathy in association with allergic disorders of the skin and respiratory tract.
  • Monoclonal gammopathy is a condition characterized by the abnormal proliferation of a single clone of plasma cells, which produces a homogeneous monoclonal protein.
  • We report 11 cases of monoclonal gammopathy presenting to practicing allergists (>2.5% of those screened) primarily in association with dermatologic disorders, i.e., urticaria, angioedema, and nonspecific dermatitis, but also with allergic respiratory disorders, i.e., allergic rhinitis, chronic sinusitis, and asthma.
  • Monoclonal gammopathy, angioedema, urticaria, allergic respiratory disorders, and sinusitis could be linked through antigenic stimulation as a trigger, either infectious, as in chronic sinusitis; self-antigens, as in autoimmunity; or the monoclonal gammopathy itself, causing idiotype-anti-idiotype immune complexes and inflammatory disease.
  • The allergist, dermatologist, otolaryngologist, and primary care physician should all maintain a high index of suspicion for the occurrence of monoclonal gammopathy in the "allergic" population.
  • When monoclonal gammopathy is found, the presence of light chains in the urine should be assessed and the patient should be referred for prompt hematology-oncology evaluation with periodic monitoring for the development of plasma cell dyscrasias.
  • Additional prospective study is necessary to determine the true prevalence of monoclonal gammopathy in the population presenting to the practicing allergist.

  • MedlinePlus Health Information. consumer health - Hives.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16724632.001).
  • [ISSN] 1088-5412
  • [Journal-full-title] Allergy and asthma proceedings
  • [ISO-abbreviation] Allergy Asthma Proc
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Pepe J, Petrucci MT, Nofroni I, Fassino V, Diacinti D, Romagnoli E, Minisola S: Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol; 2006 Sep;134(5):485-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance.
  • The possible relationships between biochemical measurements and both densitometric and radiographic indexes of skeletal fragility were evaluated in 65 postmenopausal women with monoclonal gammopathy of undetermined significance (MGUS).
  • There was a significantly higher prevalence of vertebral fractures in the MGUS group compared with a control population (P < or = 0.001).
  • The MGUS patients were then grouped according to the presence or absence of at least one mild vertebral fracture.
  • Patients with fractures (Fx, n=34) were older (62.8 +/- 6.1 years), with long-standing disease (8.8 +/- 7.1 years) when compared with those without fractures (NFx, n=31; 59.7 +/- 5.0 years, P < or = 0.05 and 5.8 +/- 4.1 years, P < or = 0.05).
  • The receptor activator of nuclear factor kappa-B ligand/osteoprotegerin ratio was higher in Fx compared with NFx (0.092 +/- 0.018 vs. 0.082 +/- 0.020; P < or = 0.05).
  • Lumbar spine (0.811 +/- 0.14 vs. 0.956 +/- 0.12 g/cm2), femoral neck (0.660 +/- 0.09 vs. 0.747 +/- 0.10 g/cm2) and total bone mineral density (BMD) (0.788 +/- 0.11 vs. 0.884 +/- 0.11 g/cm2) were lower (all P < or = 0.001) in FxMGUS compared with Nfx patients.
  • This study provides an indication for the measurement of BMD in MGUS patients, as a means of predicting vertebral fractures, especially in those that are asymptomatic.
  • [MeSH-major] Bone Density. Lumbar Vertebrae. Monoclonal Gammopathy of Undetermined Significance / physiopathology. Spinal Fractures / physiopathology

  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848794.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Membrane Glycoproteins; 0 / Osteoprotegerin; 0 / RANK Ligand; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF11A protein, human; 0 / TNFRSF11B protein, human; 0 / TNFSF11 protein, human
  •  go-up   go-down


47. van Rhee F: Light-chain MGUS: implications for clinical practice. Lancet; 2010 May 15;375(9727):1670-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Light-chain MGUS: implications for clinical practice.
  • [MeSH-major] Immunoglobulin Light Chains / blood. Monoclonal Gammopathy of Undetermined Significance / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Middle Aged. Multiple Myeloma / etiology. Precancerous Conditions / complications. Precancerous Conditions / diagnosis. Precancerous Conditions / epidemiology. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet. 2010 May 15;375(9727):1721-8 [20472173.001]
  • (PMID = 20472153.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains
  •  go-up   go-down


48. Maddox JM, Anderson JA, Plews D, Ludlam CA: Management of acquired von Willebrand's syndrome in a patient requiring major surgery. Haemophilia; 2005 Nov;11(6):633-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a patient with acquired von Willebrand's syndrome and a monoclonal gammopathy of undetermined significance who required cystectomy for relapsed transitional cell carcinoma (TCC) of the bladder.
  • We demonstrated that infused von Willebrand factor (VWF) containing factor VIII concentrates had an unacceptably short half-life, but that this was significantly prolonged following combined therapy with plasma exchange and intravenous immunoglobulin (IVIgG).
  • Levels again fell on the fifth postoperative day with the development of a Staphylococcus aureus septicaemia.
  • At this point bleeding occurred from a surgical drain site requiring 'factor VIII inhibitor bypass activity' to secure haemostasis while further plasma exchange and IVIgG were administered.
  • Now 5 years later, there is no evidence of recurrence of the TCC or progression of the monoclonal gammopathy.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Urinary Bladder Neoplasms / surgery. von Willebrand Diseases / drug therapy
  • [MeSH-minor] Blood Loss, Surgical / prevention & control. Factor VIII / therapeutic use. Humans. Immunoglobulins, Intravenous / therapeutic use. Male. Middle Aged. Plasma Exchange / methods. Treatment Outcome. von Willebrand Factor / therapeutic use

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haemophilia. 2006 May;12(3):287-8 [16643216.001]
  • (PMID = 16236115.001).
  • [ISSN] 1351-8216
  • [Journal-full-title] Haemophilia : the official journal of the World Federation of Hemophilia
  • [ISO-abbreviation] Haemophilia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous; 0 / von Willebrand Factor; 9001-27-8 / Factor VIII
  •  go-up   go-down


49. Hartley MA, Sokol L, Caceres G, Hussein MA, List A, Pinilla-Ibarz J: Monoclonal gammopathy of undetermined significance disguised as chronic neutrophilic leukemia. Mediterr J Hematol Infect Dis; 2010;2(1):e2010002
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal gammopathy of undetermined significance disguised as chronic neutrophilic leukemia.
  • We encountered a 60-year-old woman with a medical history of diabetes mellitus, osteoporosis, peripheral vascular disease, and hypertension who had earlier presented at an outside facility with knee pain, which led to a finding of elevated neutrophil count of 35×10(9)/L.
  • Because she was otherwise asymptomatic but continued showing elevated neutrophil levels, she sought a second opinion at our facility.
  • Serum protein immunoelectrophoresis with immunofixation revealed an immunoglobulin A (IgA)-κ monoclonal gammopathy concentration of 1305 mg/dL (normal 80-350 mg/dL) but relatively normal concentrations of IgG of 840 mg/dL (620-1400 mg/dL) and IgM of 36 mg/dL (45-250 mg/dL).
  • Using clonal analysis, we found a polyclonal expression pattern in all cell types analyzed.
  • We concluded that our patient's neutrophilia may have been due to the underlying monoclonal gammopathy.
  • This is the first case in the literature of a patient with monoclonal gammopathy of undetermined significance presenting with chronic neutrophilia, mimicking chronic neutrophilic leukemia (CNL).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1996 Oct;49(10):858-60 [8943758.001]
  • [Cites] Am J Hematol. 2000 Apr;63(4):184-91 [10706761.001]
  • [Cites] Jpn J Clin Oncol. 2000 Aug;30(8):362-5 [11059343.001]
  • [Cites] Leukemia. 2001 Jan;15(1):35-40 [11243396.001]
  • [Cites] Leuk Lymphoma. 2002 Mar;43(3):649-51 [12002774.001]
  • [Cites] J Clin Pathol. 2003 Apr;56(4):292-5 [12663642.001]
  • [Cites] J Clin Pathol. 1993 Apr;46(4):297-8 [8098719.001]
  • [Cites] Am J Hematol. 1997 Jan;54(1):72-5 [8980264.001]
  • [Cites] Am J Hematol. 1998 Sep;59(1):79-82 [9723582.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):162-6 [2112978.001]
  • [Cites] Tumori. 1984 Feb 29;70(1):105-7 [6585081.001]
  • [Cites] Blood. 1993 Aug 1;82(3):1035-6 [8338936.001]
  • [Cites] Acta Haematol. 1996;95(2):140-3 [8638444.001]
  • (PMID = 21415944.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033111
  •  go-up   go-down


50. Krug BC, Schwartz IV, Lopes de Oliveira F, Alegra T, Campos Martins NL, Todeschini LA, Picon PD: The management of Gaucher disease in developing countries: a successful experience in Southern Brazil. Public Health Genomics; 2010;13(1):27-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of Gaucher disease in developing countries: a successful experience in Southern Brazil.
  • OBJECTIVE: Gaucher disease (GD) is a genetic disease caused by glucocerebrosidase deficiency.
  • GD is treated by enzyme replacement therapy (ERT) with imiglucerase, a high-cost drug provided by the Brazilian Ministry of Health (BMH).
  • This study reports the implementation of the BMH guidelines for GD in the southernmost state of the country.
  • CONCLUSIONS: The model of care of GD patients suggested by the BMH guidelines appears to be cost-effective and could be an example for management of rare diseases in underdeveloped countries.
  • [MeSH-major] Enzyme Replacement Therapy. Gaucher Disease / drug therapy. Glucosylceramidase / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Brazil. Child. Disease Management. Female. Follow-Up Studies. Humans. Liver / drug effects. Liver / pathology. Male. Middle Aged. Patient Compliance. Practice Guidelines as Topic. Spleen / drug effects. Spleen / pathology. Surveys and Questionnaires

  • Genetic Alliance. consumer health - BabysFirstTest - Gaucher Disease.
  • Genetic Alliance. consumer health - Gaucher Disease.
  • MedlinePlus Health Information. consumer health - Gaucher Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 S. Karger AG, Basel.
  • (PMID = 19407439.001).
  • [ISSN] 1662-8063
  • [Journal-full-title] Public health genomics
  • [ISO-abbreviation] Public Health Genomics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 3.2.1.45 / Glucosylceramidase; EC 3.2.1.45 / imiglucerase
  •  go-up   go-down






Advertisement